Effective June 17, 2019, Anti-Müllerian Hormone (AMH) testing will change from a sendout reference test to Mayo Clinic Laboratories to an in-house test performed by Spectrum Health Regional Laboratory.
With the change in testing method from the manual ANSH ELISA method (Mayo) to the automated Roche cobas Elecsys® method (Spectrum Health), there will be a new reference range, as follows:
20 to 24 years 1.22 to 11.70 ng/mL
25 to 30 years 0.89 to 9.85 ng/mL
30 to 35 years 0.58 to 8.13 ng/mL
35 to 40 years 0.15 to 7.49 ng/mL
40 to 44 years 0.03 to 5.47 ng/mL
This testing reference range is validated for female patients aged 20 to 44 years and is intended to be used to assess ovarian reserve in conjunction with other clinical and laboratory findings. It is not intended to monitor women undergoing controlled ovarian stimulation in an assisted reproduction technology program. This testing is not designed to be used as a tumor marker for ovarian neoplasms.
If AMH testing is requested on pediatric patients, it will be sent to Mayo Medical Laboratories. If AMH testing is ordered on adult patients other than females aged 20 to 44 years, the results need to be interpreted by the ordering provider.
The Elecsys® AMH assay is fully automated and shows excellent laboratory performance in precision and linearity. Patient results measured with the automated Elecsys® AMH assay were highly correlated with the manual ELISA method but approximately 20% lower across the board. This AMH assay is also reported to show good correlation with transvaginal sonographic assessment of antral follicle count, but it has less variability when compared to manual testing methods.
Questions may be direct to Jennifer Stumph, M.D. or the Chemistry Department, using the “Contact Us” link above.
Anti-Müllerian Hormone (AMH): Epic Code: LAB1230502, Interface Code: 1230502, CPT Code: 83516
- Anckaert et.al Clinical Biochemistry 49 (2016) 260–267
- Emma D. Deeks. Adis Diagnostic Profile. Mol Diagn Ther(2015) 19:245–24